Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss
yahoo.com
news
2022-10-18 10:50:00

Proposed acquisition will accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide

Transaction valued at approximately $487 million plus a contingent value right for an aggregate amount up to approximately $610 million

INDIANAPOLIS and BOSTON, Oct. 18, 2022 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Akouos, Inc. (NASDAQ: AKUS) today announced a definitive agreement for Lilly to acquire Akouos, a precision genetic medicine company that is developing a portfolio of first-in-class adeno-associated viral gene therapies for the treatment of inner ear conditions, including sensorineural hearing loss.
